FI117707B - Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi - Google Patents

Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi Download PDF

Info

Publication number
FI117707B
FI117707B FI961494A FI961494A FI117707B FI 117707 B FI117707 B FI 117707B FI 961494 A FI961494 A FI 961494A FI 961494 A FI961494 A FI 961494A FI 117707 B FI117707 B FI 117707B
Authority
FI
Finland
Prior art keywords
nucleic acid
dna
protein
virus
activity
Prior art date
Application number
FI961494A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961494A (fi
FI961494A0 (fi
Inventor
Jacques Mallet
Frederic Revah
Jean-Marie Stutzmann
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI961494A publication Critical patent/FI961494A/fi
Publication of FI961494A0 publication Critical patent/FI961494A0/fi
Application granted granted Critical
Publication of FI117707B publication Critical patent/FI117707B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI961494A 1993-10-04 1996-04-03 Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi FI117707B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9311774 1993-10-04
FR9311774A FR2710846B1 (fr) 1993-10-04 1993-10-04 Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
FR9401142 1994-09-29
PCT/FR1994/001142 WO1995009916A1 (fr) 1993-10-04 1994-09-29 Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives

Publications (3)

Publication Number Publication Date
FI961494A FI961494A (fi) 1996-04-03
FI961494A0 FI961494A0 (fi) 1996-04-03
FI117707B true FI117707B (fi) 2007-01-31

Family

ID=9451499

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961494A FI117707B (fi) 1993-10-04 1996-04-03 Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi

Country Status (13)

Country Link
US (1) US7273854B1 (da)
EP (2) EP1598420A3 (da)
JP (2) JP3937446B2 (da)
AT (1) ATE311446T1 (da)
AU (1) AU698242B2 (da)
CA (1) CA2173338C (da)
DE (1) DE69434564T2 (da)
DK (1) DK0722496T3 (da)
ES (1) ES2253739T3 (da)
FI (1) FI117707B (da)
FR (1) FR2710846B1 (da)
NO (1) NO322063B1 (da)
WO (1) WO1995009916A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736915B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
FR2746815A1 (fr) * 1996-03-26 1997-10-03 Pasteur Institut Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
WO1998006753A2 (en) * 1996-08-13 1998-02-19 Trustees Of Princeton University P53 mutant
US5876972A (en) * 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
FR2781979B1 (fr) * 1998-08-05 2001-06-08 Fond Jean Dausset Ceph Modele animal presentant une deficience de la memoire et/ou des troubles comportementaux

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
EP0556231A4 (en) * 1990-09-17 1994-08-17 Univ California Method and composition for controlling proliferation of cells
EP0575518A1 (en) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6261834B1 (en) * 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5700657A (en) 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
NO961220L (no) 1996-03-26
EP1598420A3 (fr) 2007-12-12
JP3937446B2 (ja) 2007-06-27
DE69434564T2 (de) 2006-08-10
EP1598420A2 (fr) 2005-11-23
WO1995009916A1 (fr) 1995-04-13
AU7816294A (en) 1995-05-01
CA2173338A1 (fr) 1995-04-13
FI961494A (fi) 1996-04-03
NO322063B1 (no) 2006-08-07
CA2173338C (fr) 2009-05-05
JPH09503915A (ja) 1997-04-22
DK0722496T3 (da) 2006-04-03
EP0722496A1 (fr) 1996-07-24
US7273854B1 (en) 2007-09-25
ES2253739T3 (es) 2006-06-01
FI961494A0 (fi) 1996-04-03
ATE311446T1 (de) 2005-12-15
NO961220D0 (no) 1996-03-26
FR2710846A1 (fr) 1995-04-14
JP2007190020A (ja) 2007-08-02
AU698242B2 (en) 1998-10-29
DE69434564D1 (de) 2006-01-05
FR2710846B1 (fr) 1995-12-22
EP0722496B1 (fr) 2005-11-30

Similar Documents

Publication Publication Date Title
US6165990A (en) Antisense polynucleotide
US6653466B2 (en) Pharmaceutical composition for treatment of duchenne muscular dystrophy
JP2003265193A (ja) 組換えｐ５３アデノウイルス
JP2002509699A (ja) マウスおよびヒト・テロメラーゼｒｎａ成分遺伝子のプロモーター領域
JPH09502357A (ja) Ｇｒｂ３−３遺伝子、その変異体およびそれらの使用
FI117707B (fi) Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi
US6140112A (en) Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases
EP2128261B1 (en) A recombinant adenovirus comprising recombinant khp53 gene and preparation method and uses thereof
US20030219412A1 (en) Somatic gene therapy to suppress secondary cataract formation following eye surgery
US8431119B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FI120501B (fi) p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa
IL112993A (en) Recombinant viruses, their preparation and their use in gene therapy
WO2013122502A1 (ru) Фармацевтическая композиция и способ терапии нейродегенеративных заболеваний, в частности бокового амиотрофического склероза
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
JP7461687B2 (ja) 筋強直性ジストロフィー１型治療薬
JPH11506325A (ja) Δｐ６２、その変異体、核酸配列及びこれらの使用
US20080064652A1 (en) Methods and compositions for treating hypercholesterolemia
JP2024517377A (ja) 神経変性疾患に用いるための単離または人工ヌクレオチド
JP2023513188A (ja) 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤
CZ299915B6 (cs) Rekombinantní nukleová kyselina obsahující negativní regulacní elementy pro nervove specifickou expresi transgenu a její použití

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 117707

Country of ref document: FI

MA Patent expired